Ruplizumab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Ruplizumab
Monoclonal antibody
Type Whole antibody
Source Humanized (from mouse)
Target CD154
Clinical data
Trade names Antova
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
 ☒N☑Y (what is this?)  (verify)

Ruplizumab (trade name Antova) is a humanized monoclonal antibody intended for the treatment of rheumatic diseases like systemic lupus erythematosus and lupus nephritis. A study showed that the drug was associated with life-threatening thromboembolisms,[1] while another study only found thrombocytopenia.[2]

References[edit]

  1. ^ Liossis, SN; Sfikakis, PP (2004). "Costimulation blockade in the treatment of rheumatic diseases". BioDrugs. 18 (2): 95–102. doi:10.2165/00063030-200418020-00003. PMID 15046525.
  2. ^ Nakamura, M; Tanaka, Y; Satoh, T; Kawai, M; Hirakata, M; Kaburaki, J; Kawakami, Y; Ikeda, Y; Kuwana, M (2006). "Autoantibody to CD40 ligand in systemic lupus erythematosus: association with thrombocytopenia but not thromboembolism". Rheumatology (Oxford, England). 45 (2): 150–6. doi:10.1093/rheumatology/kei118. PMID 16188945.